Mouse CD14 Antibody

Detection of Mouse CD14 by Western Blot.

Western blot shows lysate of J774A.1 mouse reticulum cell sarcoma macrophage cell line. PVDF membrane was probed with 0.5 µg/mL of Goat Anti-Mouse CD14 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF982) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF017). A specific band was detected for CD14 at approximately 50-55 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

Detection of Mouse CD14 by Western Blot

Glimepiride releases CD14 from RAW 264 cells. (A) The amounts of CD14 in RAW 264 cells treated for one hour with control medium (□) or glimepiride (■) as shown. Values are means ± SD, from triplicate experiments performed 4 times, n = 12. (B) The amounts of CD14 in supernatants from RAW 264 cells treated for one hour with control medium (□) or glimepiride as shown (■). Values are means ± SD, from triplicate experiments performed 4 times, n = 12. (C) Immunoblots showing the amounts of CD14, PrPC, CD55 and caveolin in extracts from RAW 264 cells treated for 1 hour with control medium (i) or 5 μM glimepiride (ii). (D) The amounts of CD14 in cells (□) or supernatants (■) from microglial cells treated for 1 hour with control medium, 5 μM glimepiride or 5 μM glipizide. Values are mean units CD14 ± SD, from triplicate experiments performed 3 times, n = 9. *Cellular CD14 significantly less than control cells. **supernatant CD14 significantly greater than control supernatants. (E) Blot showing the amounts of CD14 in supernatants from microglial cells treated with concentrations of glimepiride as shown for one hour. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/24952384), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Mouse CD14 by Western Blot

Glimepiride releases CD14 from RAW 264 cells. (A) The amounts of CD14 in RAW 264 cells treated for one hour with control medium (□) or glimepiride (■) as shown. Values are means ± SD, from triplicate experiments performed 4 times, n = 12. (B) The amounts of CD14 in supernatants from RAW 264 cells treated for one hour with control medium (□) or glimepiride as shown (■). Values are means ± SD, from triplicate experiments performed 4 times, n = 12. (C) Immunoblots showing the amounts of CD14, PrPC, CD55 and caveolin in extracts from RAW 264 cells treated for 1 hour with control medium (i) or 5 μM glimepiride (ii). (D) The amounts of CD14 in cells (□) or supernatants (■) from microglial cells treated for 1 hour with control medium, 5 μM glimepiride or 5 μM glipizide. Values are mean units CD14 ± SD, from triplicate experiments performed 3 times, n = 9. *Cellular CD14 significantly less than control cells. **supernatant CD14 significantly greater than control supernatants. (E) Blot showing the amounts of CD14 in supernatants from microglial cells treated with concentrations of glimepiride as shown for one hour. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/24952384), licensed under a CC-BY license. Not internally tested by R&D Systems.